SlideShare a Scribd company logo
O
scarde
Vries
Valpreventie
Introduction
§  30 % of all people 65 and older fall ≥ once/year
§  15 % falls ≥ twice/year.
§  10% leads to injuries
§  5 % leads to fractures: 1-2% hip fracture
§  Big impact on quality of life.
§  24% of 55 yr and over dies within a year following a hip fracture
O
scarde
Vries
Valpreventie
O
scarde
Vries
Valpreventie
Increased fall risk
§  Risk factors:
§  Age
§  Dementia
§  Diminished visual acuity
§  Low body weight
§  Gait disorder
§  Prior fall
§  ≥ 4 generic drugs
§  Psychofarmacologicaly active drugs
§  Orthostatic hypotension
§  Interaction intrinsic/extrinsic factors
O
scarde
Vries
Valpreventie
Increased fall risk
§  Risk factors:
§  Age
§  Dementia
§  Diminished visual acuity
§  Low body weight
§  Gait disorder
§  Prior fall
§  ≥ 4 generic drugs
§  Psychofarmacologicaly active drugs
§  Orthostatic hypotension
§  Interaction intrinsic/extrinsic factors
O
scarde
Vries
Valpreventie
Longitudinal Aging Study Amsterdam
§  1992: inclusion of 3107 participants 65 yr and
older in and around Zwolle, Oss and
Amsterdam
§  1995/1996: medical interview of 1509
participants
§  Fall registration during 3 years
O
scarde
Vries
Valpreventie
Benzodiazepines
§  Screening-instrument (STOPP):
§  Especially avoid long-acting
benzodiazepines (half-life ≥ 24h) because
of increased fall risk.
O
scarde
Vries
Valpreventie
STOPP criteria
Gallagher et al, Age and Ageing 2008; 37: 673-9
O
scarde
Vries
Valpreventie
STOPP criteria
Gallagher et al, Age and Ageing 2008; 37: 673-9
O
scarde
Vries
Valpreventie
Benzodiazepines
§  Screening-instrument (STOPP):
§  Especially avoid long-acting
benzodiazepines (half-life ≥ 24h) because
of increased fall risk.
§  Hypothese:
§  Short-acting benzodiazepines (T1/2 ≤ 10h)
are also associated with an increased fall
risk.
O
scarde
Vries
Valpreventie
Benzodiazepines
§  Screening-instrument (STOPP):
§  Especially avoid long-acting
benzodiazepines (half-life ≥ 24h) because
of increased fall risk.
§  Hypothese:
§  Short-acting benzodiazepines (T1/2 ≤ 10h)
are also associated with an increased fall
risk.
§  Result:
§  Short-acting benzodiazepines are
associated with an increased fall risk.
De Vries, O.J. et al. Age and Ageing 2013;0:1-7
O
scarde
Vries
Valpreventie
Antacids
§  Literature:
§  Protonpump inhibitor use is associated with increased fracture
incidence.
§  Hypothesis:
§  PPI use is associated with more falls and fractures than other
antacids
§  Results:
§  PPI use is not associated with increased fall incidence
§  H2-blocker is associated with increased fall incidence.
O
scarde
Vries
Valpreventie
Frailty
§  Literature:
§  Physical frailty is associated with increased fall risk
§  Hypothesis:
§  Frailty according to LASA is also associated with increased fall
risk.
§  Result:
§  Frailty according to LASA is associated with increased fall risk.
§  Prior falls are at least as predictive.
De Vries O.J. et al. Osteoporosis International 2013; 24:2397-403
O
scarde
Vries
Valpreventie
Robinovitch S.N. et al. Lancet 2013;381:47-54
O
scarde
Vries
Valpreventie
Video capture of the circumstances of falls in elderly
people residing in long-term care: an observational study.
§  227 falls of 130 persons
(mean age 78 yr, SD 10)
§  Activities during fall:
§  Walking forward 24%
§  Standing 13%
§  Sitting down 12%
§  Start walking 9%
§  Rising from a chair 9%
§  Cause of fall:
§  Weight shifting 41%
§  Trip or stumble 21%
§  Hit or bump 11%
§  Loss of support 11%
§  Collapse 11%
§  Slipping 3%
Robinovitch et al. Lancet 2013;381:47-54.
O
scarde
Vries
Valpreventie
http://www.thelancet/cms/attachment/2024445407/2044188965/mmc1.mp4
O
scarde
Vries
Valpreventie
CBO guideline (2004)
“Prevention of falls in older persons”
O
scarde
Vries
Valpreventie
The CBO fall guideline recommends:
§  Medication evaluation
§  Balance and strength training
§  Restore visual acuity
§  Safety in and around home
§  Estimate fracture risk
§  Consider evaluation of heart rhythm disorders
§  Possibly the highest risk reduction can be achieved in
high risk older persons.
O
scarde
Vries
Valpreventie
Multifactorial fall prevention study
§  Hypothesis:
§  Multifactorial analysis and intervention in older
persons with increased fall risk leads to prevention of
new falls.
§  Method:
§  217 older persons in and around Amsterdam
§  Recent fall (ED or general practitioner)
§  Intervention and control group(106 vs 111)
§  1 year fall follow-up (calendar)
§  After 1 year measurement of QoL, mobility and
mood.
O
scarde
Vries
Valpreventie
Multifactorial fall prevention study
§  Results:
§  No difference between intervention and control group in time to
first fall.
§  In both groups decrease of the number of falls.
§  No differences in secondary outcomes apart from mortality.
§  Discussion:
§  A lot of interventions in the control group.
§  Most potential participants refused: selection of the most
motivated.
§  The type of physical therapy possibly led to increased fall risk.
O
scarde
Vries
Valpreventie
Medication reduction fall prevention
§  Hypothesis:
§  Stopping or reducing fall-risk-increasing drugs in high
risk older persons leads to prevention of new falls.
§  Method:
§  612 older persons in and around Rotterdam and
Amsterdam
§  Recent fall (ED)
§  Intervention and control group (319 vs 293)
§  1 year registration of falls, GP and ED visits.
§  After 1 year measurement of QoL.
O
scarde
Vries
Valpreventie
Medication reduction fall prevention
§  Results:
§  No difference in time to 1st or 2nd fall nor in number of falls.
§  40% of the FRIDs were necessary.
§  36% of the medication reduction interventions failed.
§  Discussion:
§  ≥50% of the FRIDs were not discontinued; compliance,
dependence, necessity?
§  Possibly better effect with long-term physician-patient relation.
O
scarde
Vries
Valpreventie
Meta-analysis
§  Gillespie LD, et al. Interventions for preventing falls in
older people living in the community. Cochrane
Database Syst Rev. 2012
§  159 trials with 79,193 community dwelling participants
§  Results:
§  Physical therapy or tai-chi: reduces both fall risk
and fall rate.
§  Multifactorial fall prevention: reduces only fall rate.
O
scarde
Vries
Valpreventie
Future
§  Studies of the relation between risk factors and
effectivity of different interventions.
§  Studies of more effective fall prevention: medication,
physical therapy, reduction of fear of falls, etc.
§  Clinically relevant and irrespective of dogmas
O
scarde
Vries
O
scarde
Vries

More Related Content

Similar to Seminar 28-04-2015 - Fall prevention Oscar de Vries

Mary Sepulveda PHE556
Mary Sepulveda PHE556Mary Sepulveda PHE556
Mary Sepulveda PHE556
Mary Sepulveda
 
Comparative study to assess the Effect of Standing Position & Sitting Positio...
Comparative study to assess the Effect of Standing Position & Sitting Positio...Comparative study to assess the Effect of Standing Position & Sitting Positio...
Comparative study to assess the Effect of Standing Position & Sitting Positio...
Kailash Nagar
 
ILS Position Statement: Seizure Disorders in Lifesaving and Lifeguarding
ILS Position Statement: Seizure Disorders in Lifesaving and LifeguardingILS Position Statement: Seizure Disorders in Lifesaving and Lifeguarding
ILS Position Statement: Seizure Disorders in Lifesaving and Lifeguarding
ILS - International Life Saving Federation
 
Cardiovascular problems in Elderly
Cardiovascular problems in ElderlyCardiovascular problems in Elderly
Cardiovascular problems in Elderly
Toufiqur Rahman
 
Seshadri Sundararajan.Adithya
Seshadri Sundararajan.AdithyaSeshadri Sundararajan.Adithya
Seshadri Sundararajan.Adithya
Adithya Seshadri Sundararajan
 
Healthstance Men's Health Awareness
Healthstance Men's Health AwarenessHealthstance Men's Health Awareness
Healthstance Men's Health Awareness
Alan Wedal
 
Geriatric Trauma_January 2011
Geriatric Trauma_January 2011Geriatric Trauma_January 2011
Geriatric Trauma_January 2011
dbakes
 
Whats New in AMD - 2015
Whats New in AMD - 2015Whats New in AMD - 2015
Whats New in AMD - 2015
Rick Trevino
 
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Effects of aspirin for primary prevention in persons with Diabetes mellitusEffects of aspirin for primary prevention in persons with Diabetes mellitus
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Shadab Ahmad
 
Afib guidelines
Afib guidelinesAfib guidelines
Afib guidelines
DR RML DELHI
 
Down Syndrome
Down SyndromeDown Syndrome
Down Syndrome
Mugemana Henri Paterne
 
Grading rubric for Falls prevention program project P
 Grading rubric for Falls prevention program project P Grading rubric for Falls prevention program project P
Grading rubric for Falls prevention program project P
MargaritoWhitt221
 
Grading rubric for falls prevention program project p
 Grading rubric for falls prevention program project p Grading rubric for falls prevention program project p
Grading rubric for falls prevention program project p
Vivan17
 
Why should we measure endothelial function
Why should we measure endothelial functionWhy should we measure endothelial function
Why should we measure endothelial function
Endothelix
 
Hd o dp en ancianos fragiles
Hd o dp en ancianos fragilesHd o dp en ancianos fragiles
Hd o dp en ancianos fragiles
Hemer Hadyn Calderon Alvites
 
Symptoms checker
Symptoms checkerSymptoms checker
Symptoms checker
Mohan Karne
 
White paper on hcq 2020.2
White paper on hcq 2020.2White paper on hcq 2020.2
White paper on hcq 2020.2
MaylynnHughes
 
Global disease burden assessment
Global disease burden assessmentGlobal disease burden assessment
Global disease burden assessment
Praveen Nagula
 
Anticoagulation in chronic kidney disease dr. mohsen el kossi
Anticoagulation in chronic kidney disease dr. mohsen el kossiAnticoagulation in chronic kidney disease dr. mohsen el kossi
Anticoagulation in chronic kidney disease dr. mohsen el kossi
FarragBahbah
 
Updates in medicine October edition
Updates in medicine October editionUpdates in medicine October edition
Updates in medicine October edition
Virginia Mason Internal Medicine Residency
 

Similar to Seminar 28-04-2015 - Fall prevention Oscar de Vries (20)

Mary Sepulveda PHE556
Mary Sepulveda PHE556Mary Sepulveda PHE556
Mary Sepulveda PHE556
 
Comparative study to assess the Effect of Standing Position & Sitting Positio...
Comparative study to assess the Effect of Standing Position & Sitting Positio...Comparative study to assess the Effect of Standing Position & Sitting Positio...
Comparative study to assess the Effect of Standing Position & Sitting Positio...
 
ILS Position Statement: Seizure Disorders in Lifesaving and Lifeguarding
ILS Position Statement: Seizure Disorders in Lifesaving and LifeguardingILS Position Statement: Seizure Disorders in Lifesaving and Lifeguarding
ILS Position Statement: Seizure Disorders in Lifesaving and Lifeguarding
 
Cardiovascular problems in Elderly
Cardiovascular problems in ElderlyCardiovascular problems in Elderly
Cardiovascular problems in Elderly
 
Seshadri Sundararajan.Adithya
Seshadri Sundararajan.AdithyaSeshadri Sundararajan.Adithya
Seshadri Sundararajan.Adithya
 
Healthstance Men's Health Awareness
Healthstance Men's Health AwarenessHealthstance Men's Health Awareness
Healthstance Men's Health Awareness
 
Geriatric Trauma_January 2011
Geriatric Trauma_January 2011Geriatric Trauma_January 2011
Geriatric Trauma_January 2011
 
Whats New in AMD - 2015
Whats New in AMD - 2015Whats New in AMD - 2015
Whats New in AMD - 2015
 
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Effects of aspirin for primary prevention in persons with Diabetes mellitusEffects of aspirin for primary prevention in persons with Diabetes mellitus
Effects of aspirin for primary prevention in persons with Diabetes mellitus
 
Afib guidelines
Afib guidelinesAfib guidelines
Afib guidelines
 
Down Syndrome
Down SyndromeDown Syndrome
Down Syndrome
 
Grading rubric for Falls prevention program project P
 Grading rubric for Falls prevention program project P Grading rubric for Falls prevention program project P
Grading rubric for Falls prevention program project P
 
Grading rubric for falls prevention program project p
 Grading rubric for falls prevention program project p Grading rubric for falls prevention program project p
Grading rubric for falls prevention program project p
 
Why should we measure endothelial function
Why should we measure endothelial functionWhy should we measure endothelial function
Why should we measure endothelial function
 
Hd o dp en ancianos fragiles
Hd o dp en ancianos fragilesHd o dp en ancianos fragiles
Hd o dp en ancianos fragiles
 
Symptoms checker
Symptoms checkerSymptoms checker
Symptoms checker
 
White paper on hcq 2020.2
White paper on hcq 2020.2White paper on hcq 2020.2
White paper on hcq 2020.2
 
Global disease burden assessment
Global disease burden assessmentGlobal disease burden assessment
Global disease burden assessment
 
Anticoagulation in chronic kidney disease dr. mohsen el kossi
Anticoagulation in chronic kidney disease dr. mohsen el kossiAnticoagulation in chronic kidney disease dr. mohsen el kossi
Anticoagulation in chronic kidney disease dr. mohsen el kossi
 
Updates in medicine October edition
Updates in medicine October editionUpdates in medicine October edition
Updates in medicine October edition
 

More from Stichting Interdisciplinaire Werkgroep Osteoporose

IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 -  Reflectie op en implementatie van de richtlijn o...IWO Meeting 19 April 2023 -  Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 -  Romosozumab anno 2023 door Prof. Dr. W.F. LemsIWO Meeting 19 April 2023 -  Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumabIWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumab
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
Stichting Interdisciplinaire Werkgroep Osteoporose
 
16 November 2022 - Valevents en FLS
16 November 2022 - Valevents en FLS16 November 2022 - Valevents en FLS
16 November 2022 - Valevents en FLS
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den BerghIWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F LemsIWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 17 November 2021 - Luc Maartens
IWO Meeting 17 November 2021 - Luc MaartensIWO Meeting 17 November 2021 - Luc Maartens
IWO Meeting 17 November 2021 - Luc Maartens
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van OostwaardIWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van Oostwaard
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den BerghIWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 13 april 2022 - Dr. Hanna Willems
IWO Meeting 13 april 2022 - Dr. Hanna WillemsIWO Meeting 13 april 2022 - Dr. Hanna Willems
IWO Meeting 13 april 2022 - Dr. Hanna Willems
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet GeusensIWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
Stichting Interdisciplinaire Werkgroep Osteoporose
 
IWO Meeting 13 april 2022 - Prof. Kassim Javaid
IWO Meeting 13 april 2022 - Prof. Kassim JavaidIWO Meeting 13 april 2022 - Prof. Kassim Javaid
IWO Meeting 13 april 2022 - Prof. Kassim Javaid
Stichting Interdisciplinaire Werkgroep Osteoporose
 

More from Stichting Interdisciplinaire Werkgroep Osteoporose (20)

IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
 
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
 
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
 
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 -  Reflectie op en implementatie van de richtlijn o...IWO Meeting 19 April 2023 -  Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
 
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 -  Romosozumab anno 2023 door Prof. Dr. W.F. LemsIWO Meeting 19 April 2023 -  Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
 
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
 
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
 
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
 
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
 
IWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumabIWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumab
 
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
 
16 November 2022 - Valevents en FLS
16 November 2022 - Valevents en FLS16 November 2022 - Valevents en FLS
16 November 2022 - Valevents en FLS
 
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den BerghIWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
 
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F LemsIWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
 
IWO Meeting 17 November 2021 - Luc Maartens
IWO Meeting 17 November 2021 - Luc MaartensIWO Meeting 17 November 2021 - Luc Maartens
IWO Meeting 17 November 2021 - Luc Maartens
 
IWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van OostwaardIWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van Oostwaard
 
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den BerghIWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
 
IWO Meeting 13 april 2022 - Dr. Hanna Willems
IWO Meeting 13 april 2022 - Dr. Hanna WillemsIWO Meeting 13 april 2022 - Dr. Hanna Willems
IWO Meeting 13 april 2022 - Dr. Hanna Willems
 
IWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet GeusensIWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
 
IWO Meeting 13 april 2022 - Prof. Kassim Javaid
IWO Meeting 13 april 2022 - Prof. Kassim JavaidIWO Meeting 13 april 2022 - Prof. Kassim Javaid
IWO Meeting 13 april 2022 - Prof. Kassim Javaid
 

Recently uploaded

Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 

Recently uploaded (20)

Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 

Seminar 28-04-2015 - Fall prevention Oscar de Vries

  • 2. Valpreventie Introduction §  30 % of all people 65 and older fall ≥ once/year §  15 % falls ≥ twice/year. §  10% leads to injuries §  5 % leads to fractures: 1-2% hip fracture §  Big impact on quality of life. §  24% of 55 yr and over dies within a year following a hip fracture O scarde Vries
  • 4. Valpreventie Increased fall risk §  Risk factors: §  Age §  Dementia §  Diminished visual acuity §  Low body weight §  Gait disorder §  Prior fall §  ≥ 4 generic drugs §  Psychofarmacologicaly active drugs §  Orthostatic hypotension §  Interaction intrinsic/extrinsic factors O scarde Vries
  • 5. Valpreventie Increased fall risk §  Risk factors: §  Age §  Dementia §  Diminished visual acuity §  Low body weight §  Gait disorder §  Prior fall §  ≥ 4 generic drugs §  Psychofarmacologicaly active drugs §  Orthostatic hypotension §  Interaction intrinsic/extrinsic factors O scarde Vries
  • 6. Valpreventie Longitudinal Aging Study Amsterdam §  1992: inclusion of 3107 participants 65 yr and older in and around Zwolle, Oss and Amsterdam §  1995/1996: medical interview of 1509 participants §  Fall registration during 3 years O scarde Vries
  • 7. Valpreventie Benzodiazepines §  Screening-instrument (STOPP): §  Especially avoid long-acting benzodiazepines (half-life ≥ 24h) because of increased fall risk. O scarde Vries
  • 8. Valpreventie STOPP criteria Gallagher et al, Age and Ageing 2008; 37: 673-9 O scarde Vries
  • 9. Valpreventie STOPP criteria Gallagher et al, Age and Ageing 2008; 37: 673-9 O scarde Vries
  • 10. Valpreventie Benzodiazepines §  Screening-instrument (STOPP): §  Especially avoid long-acting benzodiazepines (half-life ≥ 24h) because of increased fall risk. §  Hypothese: §  Short-acting benzodiazepines (T1/2 ≤ 10h) are also associated with an increased fall risk. O scarde Vries
  • 11. Valpreventie Benzodiazepines §  Screening-instrument (STOPP): §  Especially avoid long-acting benzodiazepines (half-life ≥ 24h) because of increased fall risk. §  Hypothese: §  Short-acting benzodiazepines (T1/2 ≤ 10h) are also associated with an increased fall risk. §  Result: §  Short-acting benzodiazepines are associated with an increased fall risk. De Vries, O.J. et al. Age and Ageing 2013;0:1-7 O scarde Vries
  • 12. Valpreventie Antacids §  Literature: §  Protonpump inhibitor use is associated with increased fracture incidence. §  Hypothesis: §  PPI use is associated with more falls and fractures than other antacids §  Results: §  PPI use is not associated with increased fall incidence §  H2-blocker is associated with increased fall incidence. O scarde Vries
  • 13. Valpreventie Frailty §  Literature: §  Physical frailty is associated with increased fall risk §  Hypothesis: §  Frailty according to LASA is also associated with increased fall risk. §  Result: §  Frailty according to LASA is associated with increased fall risk. §  Prior falls are at least as predictive. De Vries O.J. et al. Osteoporosis International 2013; 24:2397-403 O scarde Vries
  • 14. Valpreventie Robinovitch S.N. et al. Lancet 2013;381:47-54 O scarde Vries
  • 15. Valpreventie Video capture of the circumstances of falls in elderly people residing in long-term care: an observational study. §  227 falls of 130 persons (mean age 78 yr, SD 10) §  Activities during fall: §  Walking forward 24% §  Standing 13% §  Sitting down 12% §  Start walking 9% §  Rising from a chair 9% §  Cause of fall: §  Weight shifting 41% §  Trip or stumble 21% §  Hit or bump 11% §  Loss of support 11% §  Collapse 11% §  Slipping 3% Robinovitch et al. Lancet 2013;381:47-54. O scarde Vries
  • 17. Valpreventie CBO guideline (2004) “Prevention of falls in older persons” O scarde Vries
  • 18. Valpreventie The CBO fall guideline recommends: §  Medication evaluation §  Balance and strength training §  Restore visual acuity §  Safety in and around home §  Estimate fracture risk §  Consider evaluation of heart rhythm disorders §  Possibly the highest risk reduction can be achieved in high risk older persons. O scarde Vries
  • 19. Valpreventie Multifactorial fall prevention study §  Hypothesis: §  Multifactorial analysis and intervention in older persons with increased fall risk leads to prevention of new falls. §  Method: §  217 older persons in and around Amsterdam §  Recent fall (ED or general practitioner) §  Intervention and control group(106 vs 111) §  1 year fall follow-up (calendar) §  After 1 year measurement of QoL, mobility and mood. O scarde Vries
  • 20. Valpreventie Multifactorial fall prevention study §  Results: §  No difference between intervention and control group in time to first fall. §  In both groups decrease of the number of falls. §  No differences in secondary outcomes apart from mortality. §  Discussion: §  A lot of interventions in the control group. §  Most potential participants refused: selection of the most motivated. §  The type of physical therapy possibly led to increased fall risk. O scarde Vries
  • 21. Valpreventie Medication reduction fall prevention §  Hypothesis: §  Stopping or reducing fall-risk-increasing drugs in high risk older persons leads to prevention of new falls. §  Method: §  612 older persons in and around Rotterdam and Amsterdam §  Recent fall (ED) §  Intervention and control group (319 vs 293) §  1 year registration of falls, GP and ED visits. §  After 1 year measurement of QoL. O scarde Vries
  • 22. Valpreventie Medication reduction fall prevention §  Results: §  No difference in time to 1st or 2nd fall nor in number of falls. §  40% of the FRIDs were necessary. §  36% of the medication reduction interventions failed. §  Discussion: §  ≥50% of the FRIDs were not discontinued; compliance, dependence, necessity? §  Possibly better effect with long-term physician-patient relation. O scarde Vries
  • 23. Valpreventie Meta-analysis §  Gillespie LD, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012 §  159 trials with 79,193 community dwelling participants §  Results: §  Physical therapy or tai-chi: reduces both fall risk and fall rate. §  Multifactorial fall prevention: reduces only fall rate. O scarde Vries
  • 24. Valpreventie Future §  Studies of the relation between risk factors and effectivity of different interventions. §  Studies of more effective fall prevention: medication, physical therapy, reduction of fear of falls, etc. §  Clinically relevant and irrespective of dogmas O scarde Vries